vs
美国国际集团（AII）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
美国国际集团的季度营收约是Day One Biopharmaceuticals, Inc.的1.7倍（$68.1M vs $39.8M），美国国际集团净利率更高（30.7% vs -49.6%，领先80.2%）
美国国际集团（AIG）是一家美国跨国金融保险集团，业务遍及全球80多个国家和地区，截至2023年共有雇员25200人。集团核心业务分为三大板块：一般保险、人寿与退休服务，另设有一家独立的科技赋能子公司。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
AII vs DAWN — 直观对比
营收规模更大
AII
是对方的1.7倍
$39.8M
净利率更高
AII
高出80.2%
-49.6%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.1M | $39.8M |
| 净利润 | $20.9M | $-19.7M |
| 毛利率 | — | — |
| 营业利润率 | 43.0% | -60.9% |
| 净利率 | 30.7% | -49.6% |
| 营收同比 | — | -57.6% |
| 净利润同比 | — | -153.3% |
| 每股收益（稀释后） | $0.58 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIIDAWN
| Q4 25 | $68.1M | — | ||
| Q3 25 | $62.0M | $39.8M | ||
| Q2 25 | $74.5M | $33.9M | ||
| Q1 25 | $71.9M | $30.8M | ||
| Q3 24 | — | $93.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 |
净利润AIIDAWN
| Q4 25 | $20.9M | — | ||
| Q3 25 | $13.2M | $-19.7M | ||
| Q2 25 | $27.5M | $-30.3M | ||
| Q1 25 | $38.1M | $-36.0M | ||
| Q3 24 | — | $37.0M | ||
| Q1 24 | — | $-62.4M | ||
| Q3 23 | — | $-46.1M |
营业利润率AIIDAWN
| Q4 25 | 43.0% | — | ||
| Q3 25 | 30.3% | -60.9% | ||
| Q2 25 | 32.3% | -103.1% | ||
| Q1 25 | 59.7% | -133.5% | ||
| Q3 24 | — | 31.6% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
净利率AIIDAWN
| Q4 25 | 30.7% | — | ||
| Q3 25 | 21.2% | -49.6% | ||
| Q2 25 | 36.9% | -89.4% | ||
| Q1 25 | 53.0% | -117.0% | ||
| Q3 24 | — | 39.5% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
每股收益（稀释后）AIIDAWN
| Q4 25 | $0.58 | — | ||
| Q3 25 | $0.67 | $-0.19 | ||
| Q2 25 | $1.62 | $-0.29 | ||
| Q1 25 | $2.78 | $-0.35 | ||
| Q3 24 | — | $0.38 | ||
| Q1 24 | — | $-0.72 | ||
| Q3 23 | — | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.0M | $451.6M |
| 总债务越低越好 | $618.0K | — |
| 股东权益账面价值 | $337.0M | $450.9M |
| 总资产 | $1.2B | $513.8M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AIIDAWN
| Q4 25 | $222.0M | — | ||
| Q3 25 | $171.9M | $451.6M | ||
| Q2 25 | $259.6M | $453.1M | ||
| Q1 25 | $236.4M | $473.0M | ||
| Q3 24 | — | $558.4M | ||
| Q1 24 | — | $317.9M | ||
| Q3 23 | — | $405.5M |
总债务AIIDAWN
| Q4 25 | $618.0K | — | ||
| Q3 25 | $721.0K | — | ||
| Q2 25 | $824.0K | — | ||
| Q1 25 | $926.0K | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
股东权益AIIDAWN
| Q4 25 | $337.0M | — | ||
| Q3 25 | $315.9M | $450.9M | ||
| Q2 25 | $301.9M | $460.8M | ||
| Q1 25 | $186.1M | $479.5M | ||
| Q3 24 | — | $555.5M | ||
| Q1 24 | — | $296.8M | ||
| Q3 23 | — | $389.6M |
总资产AIIDAWN
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.4B | $513.8M | ||
| Q2 25 | $1.6B | $519.0M | ||
| Q1 25 | $1.1B | $534.4M | ||
| Q3 24 | — | $600.8M | ||
| Q1 24 | — | $326.6M | ||
| Q3 23 | — | $414.2M |
负债/权益比AIIDAWN
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $138.2M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $133.2M | — |
| 自由现金流率自由现金流/营收 | 195.6% | — |
| 资本支出强度资本支出/营收 | 7.4% | 0.0% |
| 现金转化率经营现金流/净利润 | 6.62× | — |
| 过去12个月自由现金流最近4个季度 | $216.1M | — |
8季度趋势，按日历期对齐
经营现金流AIIDAWN
| Q4 25 | $138.2M | — | ||
| Q3 25 | $-7.5M | $-5.8M | ||
| Q2 25 | $27.4M | $-24.8M | ||
| Q1 25 | $68.1M | $-59.0M | ||
| Q3 24 | — | $50.8M | ||
| Q1 24 | — | $-49.7M | ||
| Q3 23 | — | $-37.1M |
自由现金流AIIDAWN
| Q4 25 | $133.2M | — | ||
| Q3 25 | $-11.9M | — | ||
| Q2 25 | $26.9M | $-24.8M | ||
| Q1 25 | $68.0M | $-59.3M | ||
| Q3 24 | — | $50.0M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-37.1M |
自由现金流率AIIDAWN
| Q4 25 | 195.6% | — | ||
| Q3 25 | -19.2% | — | ||
| Q2 25 | 36.1% | -73.2% | ||
| Q1 25 | 94.6% | -192.8% | ||
| Q3 24 | — | 53.4% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
资本支出强度AIIDAWN
| Q4 25 | 7.4% | — | ||
| Q3 25 | 7.2% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 0.2% | 1.0% | ||
| Q3 24 | — | 0.8% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
现金转化率AIIDAWN
| Q4 25 | 6.62× | — | ||
| Q3 25 | -0.57× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.79× | — | ||
| Q3 24 | — | 1.37× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AII
暂无分部数据
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
